BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
作者信息
Stuver Robert, Mian Agrima, Brown Samantha, Devlin Sean, Caimi Paolo F, Chinapen Stephanie, Dahi Parastoo, Dean Robert, Epstein-Peterson Zachary D, Hill Brian, Horwitz Steven M, Lahoud Oscar, Lin Richard, Moskowitz Alison J, Sauter Craig, Shah Gunjan, Winter Alison, Jagadeesh Deepa, Scordo Michael
机构信息
Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.
出版信息
Am J Hematol. 2024 Jun;99(6):1180-1183. doi: 10.1002/ajh.27291. Epub 2024 Mar 25.
Abstract
摘要
相似文献
1
BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.对于接受自体造血细胞移植大剂量治疗的外周T细胞淋巴瘤患者，BEAM方案与药代动力学导向的BuCyVP16预处理方案的比较。
Am J Hematol. 2024 Jun;99(6):1180-1183. doi: 10.1002/ajh.27291. Epub 2024 Mar 25.
2
Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma.难治性/复发性B细胞非霍奇金淋巴瘤患者在自体干细胞移植加嵌合抗原受体T细胞治疗前，卡莫司汀、依托泊苷、阿糖胞苷和美法仑（BEAM）方案与卡莫司汀、依托泊苷、阿糖胞苷、美法仑和氟达拉滨（BEAMF）方案的预后差异。
Cytotherapy. 2024 May;26(5):456-465. doi: 10.1016/j.jcyt.2024.01.012. Epub 2024 Feb 19.
3
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma.BEAM 方案与 BUCYVP16 方案在 Hodgkin 淋巴瘤患者自体造血干细胞移植前的预处理效果比较。
Biol Blood Marrow Transplant. 2019 Jun;25(6):1107-1115. doi: 10.1016/j.bbmt.2019.01.032. Epub 2019 Feb 1.
4
Mitoxantrone-Based Novel Conditioning Regimen Leads to Great Survival Benefit in Peripheral T-Cell Lymphoma Compared to BEAM Regimen.与BEAM方案相比，基于米托蒽醌的新型预处理方案可使外周T细胞淋巴瘤患者获得显著的生存获益。
Cancer Med. 2024 Dec;13(23):e70476. doi: 10.1002/cam4.70476.
5
Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma.钇-90 抗 CD25 BEAM 预处理方案用于外周 T 细胞淋巴瘤的自体造血细胞移植。
Blood Adv. 2024 Sep 24;8(18):4812-4822. doi: 10.1182/bloodadvances.2023012497.
6
Cisplatin as a Viable and Secure Alternative to Carmustine in BEAM-Based Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Patients with Lymphoma.顺铂作为卡莫司汀在 BEAM 为基础的预处理方案中替代物用于淋巴瘤患者自体造血干细胞移植的可行性和安全性研究。
Transplant Proc. 2024 Jul-Aug;56(6):1446-1453. doi: 10.1016/j.transproceed.2024.05.034. Epub 2024 Jul 27.
7
BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant.BEAM与FEAM高剂量化疗：对接受自体干细胞移植的淋巴瘤患者的回顾性研究。
Bone Marrow Transplant. 2018 Aug;53(8):1051-1054. doi: 10.1038/s41409-018-0120-x. Epub 2018 Feb 13.
8
High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation.接受自体干细胞移植的复发/难治性经典型霍奇金淋巴瘤患者中，高剂量苯达莫司汀-依托泊苷、阿霉素、阿糖胞苷、美法仑（Benda-EAM）方案与苯达莫司汀、阿霉素、阿糖胞苷、美法仑（BEAM）方案的对比研究
Bone Marrow Transplant. 2019 Mar;54(3):481-484. doi: 10.1038/s41409-018-0328-9. Epub 2018 Aug 31.
9
Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas.马利兰、依托泊苷、阿糖胞苷和苯丙氨酸氮芥作为外周 T 细胞淋巴瘤自体干细胞移植的大剂量方案。
Ann Hematol. 2021 Jan;100(1):189-196. doi: 10.1007/s00277-020-04309-7. Epub 2020 Nov 17.
10
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.BEAM 和 FEAM 方案用于淋巴瘤自体造血干细胞移植的预处理方案比较：一项来自意大利淋巴瘤基金会 1038 例患者的观察性研究。
Biol Blood Marrow Transplant. 2018 Sep;24(9):1814-1822. doi: 10.1016/j.bbmt.2018.05.018. Epub 2018 May 29.
引用本文的文献
1
Mitoxantrone-Based Novel Conditioning Regimen Leads to Great Survival Benefit in Peripheral T-Cell Lymphoma Compared to BEAM Regimen.与BEAM方案相比，基于米托蒽醌的新型预处理方案可使外周T细胞淋巴瘤患者获得显著的生存获益。
Cancer Med. 2024 Dec;13(23):e70476. doi: 10.1002/cam4.70476.
本文引用的文献
1
Poor outcome of CHOEP induction followed by gemcitabine/busulfan/melphalan high-dose therapy and stem cell rescue for patients with newly diagnosed peripheral T-cell lymphoma.对于新诊断的外周T细胞淋巴瘤患者，采用CHOEP诱导化疗后序贯吉西他滨/白消安/美法仑大剂量化疗及干细胞解救治疗，结果欠佳。
Bone Marrow Transplant. 2022 Nov;57(11):1719-1720. doi: 10.1038/s41409-022-01784-6. Epub 2022 Aug 22.
2
Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study.年龄<65 岁的 II 期至 IV 期 PTCL 患者中依托泊苷和 ASCT 对生存的影响：一项基于人群的队列研究。
Blood. 2022 Sep 1;140(9):1009-1019. doi: 10.1182/blood.2021015114.
3
Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.在接受自体干细胞移植的非霍奇金淋巴瘤患者中，白消安的治疗剂量监测与降低复发风险相关。
Biol Blood Marrow Transplant. 2020 Feb;26(2):262-271. doi: 10.1016/j.bbmt.2019.09.033. Epub 2019 Oct 11.
4
BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas.用于非霍奇金淋巴瘤自体干细胞移植的BEAM或BUCYVP16预处理方案。
Bone Marrow Transplant. 2019 Oct;54(10):1553-1561. doi: 10.1038/s41409-019-0463-y. Epub 2019 Feb 4.
5
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.国际外周T细胞和自然杀伤/T细胞淋巴瘤研究：病理结果与临床结局
J Clin Oncol. 2008 Sep 1;26(25):4124-30. doi: 10.1200/JCO.2008.16.4558. Epub 2008 Jul 14.
6
Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma.非霍奇金淋巴瘤患者接受白消安、依托泊苷和环磷酰胺治疗后的自体移植。
Bone Marrow Transplant. 2000 Jun;25(12):1243-8. doi: 10.1038/sj.bmt.1702433.
Zotero 插件